ESMO 2026 | Risk-stratified approaches to triplet vs duplet regimens in HR+ breast cancer

Name: Risk-stratified approaches to triplet vs duplet regimens in HR+ breast cancer
Uploaded: 2026-10-26T00:00:00Z
Duration: 58 s

Yeon Hee Park • 26 Oct 2026

ESMO 2026

Breast Cancer

Yeon Hee Park, MD, Samsung Medical Center, Seoul, South Korea, discusses a risk-stratified approach to selecting between duplet and triplet regimens for HR-positive breast cancer, emphasizing that treatment choice depends on individual patient factors rather than a one-size-fits-all strategy. Triplet regimens are preferred for patients with aggressive disease features, including short disease-free survival, high tumor burden, and aggressive clinical characteristics. However, triplet therapy is avoided in patients with significant comorbidities, advanced age, or indolent tumors, even when tumor burden is substantial. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Usually, the triplet regimen are more adopted for hormonal positive breast cancer, but it’s exactly risk-based, risk-stratified approach for the patient. So, if the patient has a really aggressive disease, such as short disease-free survival, and then also the higher tumor burden, and then highly aggressive clinical feature, and then we PREFER to incorporate the triplet than duplet. But if the patient, even in the higher tumour burden, but patient with major core morbidity and also old age, and then tumor is a kind of an indolent tumor, we prefer not to use the triplets.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

ESMO 2026 | Risk-stratified approaches to triplet vs duplet regimens in HR+ breast cancer

Transcript

More from Yeon Hee Park

Related Videos